The global antibody drug conjugate (ADC) market size was valued at USD 13.51 billion in 2025 and is predicted to hit around ...

New therapies like T-cell engagers and antibody-drug conjugates are showing survival gains in pretreated small cell lung ...

Just a few years ago, Daniel Chen, M.D., Ph.D., was spending his spare time in his backyard, sketching out designs for new ...

Key market opportunities for bispecific antibody drug conjugates (BsADCs) include their potential to revolutionize cancer treatment by targeting dual antigens, addressing tumor heterogeneity. With ...

You may have heard of the consulting firm Gartner’s technology hype cycle—the technology trigger, the peak of inflated expectations, the trough of disillusionment, the slope of enlightenment, and the ...

The conjugate space is evolving fast - moving beyond traditional ADCs into new formats like degrader-conjugates, oligonucleotide conjugates, bispecific ADCs, and more. The 4 th Novel Conjugates Summit ...

Dr. Jacob A. Sands shares how antibody-drug conjugates, such as Datroway, work to selectively target and destroy tumor cells among those with lung cancer. Antibody-drug conjugates like Datroway ...

A panelist discusses how antibody-drug conjugates like mirvetuximab should be sequenced in platinum-resistant ovarian cancer, recommending it as first-line therapy for folate receptor alpha–high ...

With advanced development capabilities in the field of ADC, BOC Sciences can provide a comprehensive selection of linkers for conjugated drug development. Linkers play a crucial role in the design of ...

Linking therapeutically active molecules to specific antibodies can help to pilot them to their designated targets and minimize side effects--especially when treating tumors. In the journal Angewandte ...